22 completed, 1 not yet recruiting, 1 terminated. 24 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 22, Not yet recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow paricalcitol: new trials by email Literature Review of paricalcitol trials Research Report on paricalcitol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal Cancer Paricalcitol, pirfenidone - Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma | Phase 2 | Not yet recruiting | Patrick Wagner, MD, FACS | 74 | 2026-09-01 | 2026-10-05 |
| Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer Paricalcitol, Gemcitabine (GEM) and Nab-paclitaxel - Advanced Pancreatic Cancer | Phase 2 | Completed | Cancer Trials Ireland | 15 | 2020-10-16 | 2024-03-06 |
| Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer Gemcitabine, Hydroxychloroquine, Nab-paclitaxel - Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Completed | Emory University | 10 | 2020-09-14 | 2026-01-23 |
| Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Paclitaxel protein bound, Cisplatin, Gemcitabine - Pancreatic Cancer | Phase 2 | Completed | Barts & The London NHS Trust | 27 | 2018-11-29 | 2025-11-21 |
| Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Paricalcitol (Zemplar) - Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | HonorHealth Research Institute | 34 | 2018-01-31 | 2026-05-12 |
| A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer Pembrolizumab, paricalcitol, placebo - Pancreatic Cancer, Pancreas Adenocarcinoma | Phase 2 | Completed | Translational Genomics Research Institute | 24 | 2017-12-27 | 2022-12-27 |
| Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Paclitaxel Protein Bound (Abraxane) - Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer | Phase 2 | Completed | HonorHealth Research Institute | 40 | 2017-05-23 | 2026-04-22 |
| Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Nivolumab, Albumin-bound paclitaxel, Paricalcitol - Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | HonorHealth Research Institute | 35 | 2016-04-01 | 2025-08-27 |
| DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients. Paricalcitol, Placebo (for paricalcitol) - Hypersensitivity | Phase 2 | Completed | Laurian Jongejan | 44 | 2015-10-01 | 2018-09-04 |
| Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes Paricalcitol, placebo - Type 2 Diabetes | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 112 | 2011-09-01 | 2017-03-03 |
| Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease Zemplar - Chronic Kidney Disease | Phase 2 / Phase 3 | Completed | Danderyd Hospital | 36 | 2010-09-01 | 2013-09-05 |
| Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease Zemplar, Placebo - Chronic Kidney Disease | Phase 2 | Completed | Erling Bjerregaard Pedersen | 30 | 2010-07-01 | 2012-01-25 |
| Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism paricalcitol, maxacalcitol - Secondary Hyperparathyroidism, Hemodialysis | Phase 2 | Completed | Abbott | 47 | 2009-10-01 | 2011-07-11 |
| Metabolic Effects of Paricalcitol Paricalcitol, Placebo - Chronic Kidney Disease | Phase 2 | Completed | University of Washington | 22 | 2009-10-01 | 2014-04-28 |
| Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism Paricalcitol, Standard therapy - Renal Transplant, Secondary Hyperparathyroidism | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 43 | 2009-09-01 | 2013-02-22 |
| Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases paricalcitol, immunoenzyme technique, laboratory biomarker analysis - Metastatic Cancer, Prostate Cancer | Phase 2 | Terminated | Wake Forest University Health Sciences | 2 | 2009-01-01 | 2018-07-06 |
| Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD) Paricalcitol - Secondary Hyperparathyroidism, Hemodialysis | Phase 2 | Completed | Abbott | 107 | 2008-07-01 | 2011-04-19 |
| Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis Maxacalcitol, Paricalcitol - Chronic Kidney Disease on Hemodialysis, Secondary Hyperparathyroidism | Phase 2 | Completed | Abbott | 153 | 2008-04-01 | 2012-01-20 |
| Vitamin D, Insulin Resistance and Inflammation in ESRD paricalcitol, cinacalcet - End Stage Renal Disease | Phase 2 | Completed | Vanderbilt University | 12 | 2008-04-01 | 2012-01-11 |
| The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules, Placebo - Diabetic Nephropathy, Chronic Kidney Disease | Phase 2 | Completed | Abbott | 281 | 2006-12-01 | 2012-01-20 |
Showing 20 of 24. Sign in to see all of them.
Renal Insufficiency, Chronic (6) · Hyperparathyroidism, Secondary (4) · Pancreatic Neoplasms (4) · Kidney Failure, Chronic (2) · Neoplasm Metastasis (2) · Proteinuria (2) · Adenocarcinoma (1) · Anemia, Refractory (1) · Anemia, Refractory, with Excess of Blasts (1) · Cardiovascular Diseases (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Nephropathies (1) · Hypersensitivity (1) · Hypocalcemia (1) · Insulin Resistance (1)
Abbott (6) · HonorHealth Research Institute (3) · Mario Negri Institute for Pharmacological Research (2) · Barts & The London NHS Trust (1) · Cancer Trials Ireland (1) · Cedars-Sinai Medical Center (1) · Danderyd Hospital (1) · Emory University (1) · Erling Bjerregaard Pedersen (1) · Laurian Jongejan (1) · Patrick Wagner, MD, FACS (1) · Renal Research Institute (1) · Translational Genomics Research Institute (1) · University of Washington (1) · Vanderbilt University (1)
United States (12) · Japan (4) · Italy (3) · Netherlands (2) · Denmark (1) · Germany (1) · Greece (1) · Ireland (1) · Poland (1) · Portugal (1) · Puerto Rico (1) · Spain (1) · Sweden (1) · Taiwan (1) · United Kingdom (1)
Erkut Borazanci, MD (3) · Alp Ikizler, MD (1) · Daniel D Von Hoff, MD, FACS (1) · Dennis Andress, MD (1) · Erling B Pedersen, Prof, MSci (1) · Gary G. Schwartz, MD, PhD, MPH (1) · H. Phillip Koeffler, MD (1) · Hideaki Harada (1) · Ian H de Boer, MD, MS (1) · Joel Z Melnick, M.D. (1) · Mebea Aklilu, MD (1) · Moriaki Kubo (1) · Nathan W Levin, MD (1) · Olatunji B. Alese, MD (1)
PMID 21055801, PMID 22913981, PMID 23787544, PMID 23889806, PMID 26496210, PMID 28511692, PMID 29104158, PMID 29386411, PMID 31370809, PMID 36645291, PMID 39730001, PMID 39846984, PMID 41535788, PMID 42268676
2008 (1), 2009 (1), P30CA012197 (1), P30CA138292 (1)